Literature DB >> 28981166

Terlipressin: Current and emerging indications in chronic liver disease.

Timothy Papaluca1, Paul Gow1.   

Abstract

Terlipressin is an analogue of vasopressin that has potent vasoactive properties and has been available for use in most countries for nearly two decades. It has both established roles and emerging indications in the management of complications of decompensated chronic liver disease. We explore historic and emerging literature regarding the use of terlipressin for a range of indications including hepatorenal syndrome, portal hypertensive bleeding, and disruptions in sodium homeostasis. Novel methods of infusion-based terlipressin administration including the beneficial effect in reduction of adverse events are explored, in addition to new indications for the use of terlipressin in decompensated cirrhosis in an outpatient setting.
© 2017 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  cirrhosis; hepatorenal syndrome; portal hypertension; terlipressin

Mesh:

Substances:

Year:  2018        PMID: 28981166     DOI: 10.1111/jgh.14009

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  10 in total

1.  Improving outcomes with pharmacotherapy to treat acute esophageal variceal bleeding.

Authors:  C E Eapen; Subramani Kandasamy
Journal:  Indian J Gastroenterol       Date:  2018-07

2.  Long-term continuous terlipressin infusion in cirrhotic patients with hepatorenal syndrome or refractory ascites awaiting liver transplantation is associated with an increase in plasma sodium.

Authors:  T McClure; B Chapman; P Hey; A Testro; P Gow
Journal:  United European Gastroenterol J       Date:  2019-09-19       Impact factor: 4.623

3.  Perioperative management of liver surgery-review on pathophysiology of liver disease and liver failure.

Authors:  Lukas Gasteiger; Stephan Eschertzhuber; Werner Tiefenthaler
Journal:  Eur Surg       Date:  2018-04-13       Impact factor: 0.953

4.  Terlipressin for the treatment of acute variceal bleeding: A systematic review and meta-analysis of randomized controlled trials.

Authors:  Xinmiao Zhou; Dhiraj Tripathi; Tingxue Song; Lichun Shao; Bing Han; Jia Zhu; Dan Han; Fufang Liu; Xingshun Qi
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.817

5.  Refractory ascites-the contemporary view on pathogenesis and therapy.

Authors:  Beata Kasztelan-Szczerbinska; Halina Cichoz-Lach
Journal:  PeerJ       Date:  2019-10-15       Impact factor: 2.984

6.  Effect of terlipressin on renal function in cirrhotic patients with acute upper gastrointestinal bleeding.

Authors:  Jingqiao Zhang; Jie Liu; Yunhai Wu; Fernando Gomes Romeiro; Giovanni Battista Levi Sandri; Xinmiao Zhou; Miaomiao Li; Xingshun Qi
Journal:  Ann Transl Med       Date:  2020-03

7.  An investigation of reconstituted terlipressin infusion stability for use in hepatorenal syndrome.

Authors:  Thi Ngoc Nhieu Bui; Su Sandar; Giuseppe Luna; Jasmine Beaman; Bruce Sunderland; Petra Czarniak
Journal:  Sci Rep       Date:  2020-12-03       Impact factor: 4.379

8.  Terlipressin effect on hepatorenal syndrome: Updated meta-analysis of randomized controlled trials.

Authors:  Mohamed M G Mohamed; Abdul Rauf; Abubakr Adam; Babikir Kheiri; Alexandre Lacasse; Hani El-Halawany
Journal:  JGH Open       Date:  2021-07-01

Review 9.  Management of Cirrhotic Ascites under the Add-on Administration of Tolvaptan.

Authors:  Takuya Adachi; Yasuto Takeuchi; Akinobu Takaki; Atsushi Oyama; Nozomu Wada; Hideki Onishi; Hidenori Shiraha; Hiroyuki Okada
Journal:  Int J Mol Sci       Date:  2021-05-25       Impact factor: 5.923

Review 10.  Vasopressin and Its Analogues: From Natural Hormones to Multitasking Peptides.

Authors:  Mladena Glavaš; Agata Gitlin-Domagalska; Dawid Dębowski; Natalia Ptaszyńska; Anna Łęgowska; Krzysztof Rolka
Journal:  Int J Mol Sci       Date:  2022-03-12       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.